DB:OQS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies.


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Nanosonics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OQS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.5%

OQS

-0.2%

DE Medical Equipment

2.4%

DE Market


1 Year Return

55.7%

OQS

38.3%

DE Medical Equipment

-0.1%

DE Market

Return vs Industry: OQS exceeded the German Medical Equipment industry which returned 38.3% over the past year.

Return vs Market: OQS exceeded the German Market which returned -0.1% over the past year.


Shareholder returns

OQSIndustryMarket
7 Day0.5%-0.2%2.4%
30 Day5.6%8.2%7.8%
90 Day5.6%25.7%-3.8%
1 Year55.7%55.7%40.0%38.3%1.5%-0.1%
3 Year128.4%128.4%126.6%122.4%-4.8%-12.1%
5 Year268.2%268.2%276.9%263.4%3.6%-9.5%

Price Volatility Vs. Market

How volatile is Nanosonics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nanosonics undervalued compared to its fair value and its price relative to the market?

171.81x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OQS (€4.12) is trading above our estimate of fair value (€3.83)

Significantly Below Fair Value: OQS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OQS is poor value based on its PE Ratio (171.8x) compared to the Medical Equipment industry average (46.3x).

PE vs Market: OQS is poor value based on its PE Ratio (171.8x) compared to the German market (19x).


Price to Earnings Growth Ratio

PEG Ratio: OQS is poor value based on its PEG Ratio (4.6x)


Price to Book Ratio

PB vs Industry: OQS is overvalued based on its PB Ratio (17.9x) compared to the DE Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Nanosonics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

37.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OQS's forecast earnings growth (37.6% per year) is above the savings rate (0.2%).

Earnings vs Market: OQS's earnings (37.6% per year) are forecast to grow faster than the German market (22.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OQS's revenue (21% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: OQS's revenue (21% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OQS's Return on Equity is forecast to be low in 3 years time (17.8%).


Next Steps

Past Performance

How has Nanosonics performed over the past 5 years?

32.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OQS has high quality earnings.

Growing Profit Margin: OQS's current net profit margins (13.2%) are lower than last year (14.9%).


Past Earnings Growth Analysis

Earnings Trend: OQS's earnings have grown significantly by 32.2% per year over the past 5 years.

Accelerating Growth: OQS's earnings growth over the past year (14.7%) is below its 5-year average (32.2% per year).

Earnings vs Industry: OQS earnings growth over the past year (14.7%) exceeded the Medical Equipment industry 8.2%.


Return on Equity

High ROE: OQS's Return on Equity (10.4%) is considered low.


Next Steps

Financial Health

How is Nanosonics's financial position?


Financial Position Analysis

Short Term Liabilities: OQS's short term assets (A$113.6M) exceed its short term liabilities (A$14.5M).

Long Term Liabilities: OQS's short term assets (A$113.6M) exceed its long term liabilities (A$4.1M).


Debt to Equity History and Analysis

Debt Level: OQS is debt free.

Reducing Debt: OQS has no debt compared to 5 years ago when its debt to equity ratio was 36.6%.

Debt Coverage: OQS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OQS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Nanosonics's current dividend yield, its reliability and sustainability?

0.11%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OQS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OQS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OQS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OQS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OQS's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Michael Kavanagh

6.58yrs

Tenure

AU$1,163,884

Compensation

Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a S ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD766.02K) is below average for companies of similar size in the German market ($USD1.48M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Kavanagh
CEO, President6.58yrsAU$1.16m0.34% A$4.3m
McGregor Grant
CFO & Company Secretary9.08yrsAU$567.33k0.20% A$2.5m
Rod Lopez
Chief Operating Officer1.17yrsAU$187.53kno data
Steven Farrugia
Chief Technology Officer2.25yrsAU$515.34kno data
Ken Shaw
Regional President of United States2.67yrsAU$659.22kno data
David Morris
Chief Strategy Officer & Regional President Asia Pacific1.25yrsAU$274.55kno data
Renee Salaberry
Chief Marketing Officer1.33yrsno datano data
Leanne Baxendale
Head of People & Culture3.17yrsno datano data
Vincent Wang
Head of Global Customer Support & Technical Servicesno dataAU$202.22kno data
Keith Koby
Senior Vice President of Sales - North America3.58yrsno datano data

2.7yrs

Average Tenure

Experienced Management: OQS's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Kavanagh
CEO, President6.58yrsAU$1.16m0.34% A$4.3m
Ronan Wright
Regional President of Europe0.67yrno datano data
Steven Sargent
Non-Executive Deputy Chairman of the Board & Lead Independent Director2.58yrsAU$100.00k0.036% A$448.3k
Maurie Stang
Non Executive Chairman of the Board13.17yrsAU$170.00k6.3% A$79.4m
Lisa E. McIntyre
Non-Executive Director0.42yrno datano data
David Fisher
Non-Executive Director18.83yrsAU$100.00k0.14% A$1.7m
Geoff Wilson
Non-Executive Director0.83yrno data0.0066% A$83.4k
Marie McDonald
Non-Executive Director3.58yrsAU$85.00k0.0065% A$82.1k

3.1yrs

Average Tenure

59yo

Average Age

Experienced Board: OQS's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nanosonics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanosonics Limited
  • Ticker: OQS
  • Exchange: DB
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$2.101b
  • Listing Market Cap: AU$1.259b
  • Shares outstanding: 300.60m
  • Website: https://www.nanosonics.com.au

Number of Employees


Location

  • Nanosonics Limited
  • 14 Mars Road
  • Lane Cove
  • New South Wales
  • 2066
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2007
OQSDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2007
NNCS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2007
NANCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2007

Biography

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare associated infections. It also provides trophon2, an ultrasound probe high level disinfection device; and trophon EPR, a device designed to disinfect intracavity and surface ultrasound probes. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 21:54
End of Day Share Price2020/05/28 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.